Get the Daily Brief
Latest Biotech News
J&J wins FDA nod for psoriasis pill – First oral IL‑23 blocker cleared
Johnson & Johnson secured U.S. Food and Drug Administration approval for icotrokinra, to be marketed as Icotyde, in patients 12 and older with moderate to severe plaque psoriasis. The approval...
Azalea’s in vivo CAR‑T clears tumors in mice: Nature paper shows proof
Azalea Therapeutics and collaborators published results in Nature demonstrating successful in vivo generation of CAR‑T cells after systemic delivery of gene‑editing particles, producing tumor...
White House lifts NIH spending hold — Grants, hiring to resume
The Office of Management and Budget (OMB) approved NIH apportionments, ending a hold that had constrained the agency’s ability to issue new research grants. NIH Director Jayanta 'Jay' Bhattacharya...
Basecamp, Anthropic, PacBio launch Trillion Gene Atlas: AI‑driven biodiversity push
Basecamp Research announced a Trillion Gene Atlas initiative in partnership with Anthropic, Ultima Genomics, Pacific Biosciences and Nvidia to massively expand environmental sequencing for...
Arvinas’ PROTAC hits brain target — ARV‑102 reduces LRRK2 in CSF >50%
Arvinas reported Phase 1 multiple‑dose data showing ARV‑102, an oral PROTAC degrader targeting LRRK2, achieved approximately 50% or greater reduction of LRRK2 protein in cerebrospinal fluid at all...
Crossbow banks $77M to advance TCR‑mimetic T‑cell engagers
Crossbow Therapeutics closed a $77 million Series B co‑led by Taiho Ventures and Arkin BioCapital to advance next‑generation T‑cell engagers into the clinic. The financing will support the Phase 1...
Structure posts injectable‑like oral GLP‑1 results — 44‑week Phase 2 shows ~16% weight loss
Structure Therapeutics disclosed Phase 2 results for aleniglipron, an oral once‑daily GLP‑1 receptor agonist, reporting up to roughly 16% placebo‑adjusted weight loss at 44 weeks. The company...
Engineered E. coli sustains intratumoral NO — Vascular normalization boosts anti‑PD‑L1 responses
Two independent reports published in Nature Biotechnology and Nature detail engineered Escherichia coli Nissle 1917 strains programmed with synthetic arginine–nitric oxide (NO) circuits that...
FDA clears Myriad’s MyChoice CDx as companion for GSK’s Zejula
Myriad Genetics received FDA approval for MyChoice CDx as a companion diagnostic to identify homologous recombination deficiency (HRD) and BRCA‑mutant advanced ovarian cancer patients eligible for...
Roche plans massive 'AI factory' — Nvidia deal to accelerate drug and diagnostic R&D
Roche announced a major expansion of its AI infrastructure in collaboration with Nvidia to accelerate drug discovery, diagnostics and biomanufacturing workflows. The company said it will deploy...
J&J’s Icotyde wins FDA approval — oral psoriasis option cleared
Johnson & Johnson announced FDA approval of icotrokinra, to be marketed as Icotyde, for moderate-to-severe plaque psoriasis in patients 12 and older. The agency’s decision converts a once-daily...
PROTAC reaches the brain... Arvinas posts central LRRK2 degradation
Arvinas presented Phase 1 multiple-dose data showing ARV-102, an oral PROTAC targeting LRRK2, achieved roughly 50% or greater reduction of LRRK2 protein in cerebrospinal fluid by day 14 and...
Oral GLP‑1 posts injectable‑like results — Structure’s aleniglipron advances
Structure Therapeutics reported Phase 2 results for aleniglipron, an oral GLP‑1 receptor agonist, showing substantial weight loss over 44 weeks that rivaled injectable competitors. Trial readouts...
Masked ADC shows responses in late‑line CRC — CytomX expands readout
CytomX released expanded cohort results from its Phase 1 study of Varsetatug masetecan (Varseta‑M), a masked EpCAM-directed antibody–drug conjugate, reporting an objective response rate of about...
Excalipoint raises $68.7M — China’s T‑cell engager push
Excalipoint Therapeutics closed a $68.7 million financing to advance multi‑platform T‑cell engager programs and a six‑program pipeline, the company said. The round comprised an earlier seed close...
Roche builds an AI factory: Nvidia pact to scale drug discovery
Roche struck a strategic agreement with Nvidia to construct a high‑capacity AI compute facility intended to accelerate drug discovery and diagnostics development. The deal will supply Roche with...
Engineered E. coli sustains tumor NO — sensitizes tumors to PD‑L1
Two independent reports published in Nature Biotechnology and accompanying coverage describe engineered Escherichia coli strains capable of sustained intratumoral nitric oxide production via...
In vivo base editing reverses disorder — new editors cut bystander edits
Nature Biotechnology published results showing in vivo base editing can reverse a genetic neurodevelopmental disorder in preclinical models, reporting phenotypic rescue after targeted...
Protein sequencing scales up — single‑molecule peptide reads emerge
Nature Biotechnology and Stanford reports unveiled complementary advances in protein sequencing. One team described a single‑molecule peptide sequencing approach that converts amino acids into...
AI meets in‑vivo functional genomics — PerturbAI’s atlas, Xaira’s X‑Cell
PerturbAI publicly released an in vivo Perturb‑seq dataset mapping gene function across 8 million brain cells, produced with partners including 10x Genomics, NVIDIA and the Allen Institute. The...